RT Journal Article
SR Electronic
T1 The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.18.20172874
DO 10.1101/2020.08.18.20172874
A1 González, María Mateos
A1 Gonzalo, Elena Sierra
A1 Lopez, Irene Casado
A1 Fernández, Francisco Arnalich
A1 Pérez, José Luis Beato
A1 Monge, Daniel Monge
A1 Núñez, Juan Antonio Vargas
A1 Fenoll, Rosa García
A1 Fernández, Carmen Suárez
A1 Castro, Santiago Jesús Freire
A1 Bailon, Manuel Mendez
A1 Fraile, Isabel Perales
A1 Madrazo, Manuel
A1 Fontan, Paula Maria Pesqueira
A1 Gamboa, Jeffrey Oskar Magallanes
A1 García, Andrés González
A1 Vieitez, Anxela Crestelo
A1 Aizpuru, Eva María Fonseca
A1 Arostegui, Asier Aranguren
A1 Erdozain, Ainara Coduras
A1 Cilleros, Carmen Martinez
A1 Amigo, Jose Loureiro
A1 Epelde, Francisco
A1 Bermejo, Carlos Lumbreras
A1 Santos, Juan Miguel Antón
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/08/21/2020.08.18.20172874.abstract
AB Objectives A decrease in blood cell counts, especially lymphocytes and eosinophils, has been described in patients with severe SARS-CoV-2 (COVID-19), but there is no knowledge of the potential role of their recovery in these patients’ prognosis. This article aims to analyse the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19.Design This work is a multicentre, retrospective, cohort study of 9,644 hospitalised patients with confirmed COVID-19 from the Spanish Society of Internal Medicine’s SEMI-COVID-19 Registry.Setting This study examined patients hospitalised in 147 hospitals throughout Spain.Participants This work analysed 9,644 patients (57.12% male) out of a cohort of 12,826 patients ≥18 years of age hospitalised with COVID-19 in Spain included in the SEMI-COVID-19 Registry as of 29 May 2020.Main outcome measures The main outcome measure of this work is the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Univariate analysis was performed to determine possible predictors of death and then multivariate analysis was carried out to control for potential confounders.Results An increase in the eosinophil count on the seventh day of hospitalisation was associated with a better prognosis, including lower mortality rates (5.2% vs 22.6% in non-recoverers, OR 0.234 [95% CI, 0.154 to 0.354]) and lower complication rates, especially regarding to development of acute respiratory distress syndrome (8% vs 20.1%, p=0.000) and ICU admission (5.4% vs 10.8%, p=0.000). Lymphocyte recovery was found to have no effect on prognosis. Treatment with inhaled or systemic glucocorticoids was not found to be a confounding factor.Conclusion Eosinophil recovery in patients with COVID-19 is a reliable marker of a good prognosis that is independent of prior treatment. This finding could be used to guide discharge decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no funding supported.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SEMI-COVID-19 Registry is an ongoing, nationwide, retrospective cohort that includes consecutive patients with a confirmed COVID-19 infection who have been hospitalised and discharged from Spanish hospitals. The registrys characteristics have been thoroughly described in other works (J M Casas-Rojo, J M Anton-Santos, J. Millan-Nunez-Cortes, C. Lumbreras-Bermejo, J M Ramos-Rincon, E. Roy-Vallejo, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry. Revista Clinica Espanola. https://doi.org/10.1016/j.rce.2020.07.003)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the manuscript.